Total Payments
$4,162
2024 Payments
$579.16
Companies
29
Transactions
240
Medicare Patients
1,869
Medicare Billing
$209,072
Payment Breakdown by Category
Food & Beverage$4,143 (99.6%)
Education$18.46 (0.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,143 | 239 | 99.6% |
| Education | $18.46 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,281 | 81 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $528.27 | 32 | $0 (2024) |
| GENZYME CORPORATION | $378.71 | 15 | $0 (2024) |
| Janssen Biotech, Inc. | $247.55 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $195.04 | 6 | $0 (2023) |
| Allergan, Inc. | $182.20 | 15 | $0 (2020) |
| QOL Medical, LLC | $168.93 | 11 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $153.23 | 8 | $0 (2017) |
| IRONWOOD PHARMACEUTICALS, INC | $145.89 | 9 | $0 (2024) |
| Celgene Corporation | $140.22 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $579.16 | 26 | GENZYME CORPORATION ($152.19) |
| 2023 | $589.69 | 28 | GENZYME CORPORATION ($158.74) |
| 2022 | $785.43 | 43 | ABBVIE INC. ($355.45) |
| 2021 | $424.84 | 26 | AbbVie Inc. ($245.42) |
| 2020 | $263.09 | 16 | AbbVie Inc. ($85.86) |
| 2019 | $448.72 | 27 | AbbVie, Inc. ($130.61) |
| 2018 | $431.67 | 32 | AbbVie, Inc. ($158.16) |
| 2017 | $639.03 | 42 | Valeant Pharmaceuticals North America LLC ($153.23) |
All Payment Transactions
240 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $2.53 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Immunology | ||||||
| 09/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.91 | General |
| Category: Immunology | ||||||
| 08/12/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: Immunology | ||||||
| 07/30/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $29.06 | General |
| Category: IMMUNOLOGY | ||||||
| 07/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Immunology | ||||||
| 07/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.55 | General |
| Category: Immunology | ||||||
| 05/29/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: IMMUNOLOGY | ||||||
| 05/23/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/13/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: THERAPY FOR CSID | ||||||
| 05/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Immunology | ||||||
| 04/29/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $14.38 | General |
| Category: GI | ||||||
| 04/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.25 | General |
| Category: Immunology | ||||||
| 04/12/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: VIROLOGY | ||||||
| 03/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Gastroenterology | ||||||
| 03/21/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Immunology | ||||||
| 03/18/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: IMMUNOLOGY | ||||||
| 03/08/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: VIROLOGY | ||||||
| 03/04/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Education | In-kind items and services | $18.46 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: Gastroenterology | ||||||
| 01/30/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/24/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: INFLAMMATION;PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 384 | 468 | $206,729 | $41,679 |
| 2022 | 8 | 402 | 512 | $217,743 | $43,947 |
| 2021 | 10 | 506 | 707 | $271,604 | $61,601 |
| 2020 | 13 | 577 | 812 | $267,105 | $61,845 |
Total Patients
1,869
Total Services
2,499
Medicare Billing
$209,072
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 147 | 216 | $59,616 | $13,753 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 68 | $26,656 | $6,430 | 24.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 26 | 26 | $24,518 | $5,384 | 22.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 42 | 42 | $33,306 | $4,689 | 14.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 55 | 56 | $33,600 | $4,646 | 13.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $14,703 | $3,466 | 23.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 18 | 18 | $13,446 | $3,107 | 23.1% |
| 82274 | Stool analysis for blood, by fecal hemoglobin determination by immunoassay | Office | 2023 | 12 | 13 | $884.00 | $202.80 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 146 | 233 | $64,308 | $14,487 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 81 | 99 | $38,808 | $8,894 | 22.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 56 | 59 | $35,400 | $4,774 | 13.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 36 | 36 | $28,548 | $4,375 | 15.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 34 | 34 | $17,238 | $4,173 | 24.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 19 | 19 | $14,193 | $3,362 | 23.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 15 | 16 | $15,088 | $3,098 | 20.5% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2022 | 15 | 16 | $4,160 | $782.80 | 18.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 192 | 351 | $90,135 | $24,055 | 26.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 87 | 120 | $44,076 | $11,824 | 26.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 53 | 53 | $26,549 | $6,038 | 22.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 54 | 59 | $35,400 | $5,650 | 16.0% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 21 | 21 | $19,803 | $4,224 | 21.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 36 | 37 | $29,341 | $3,838 | 13.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 17 | 17 | $12,699 | $3,145 | 24.8% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 15 | 15 | $11,205 | $2,273 | 20.3% |
| 82274 | Stool analysis for blood, by fecal hemoglobin determination by immunoassay | Office | 2021 | 19 | 22 | $1,496 | $337.92 | 22.6% |
About Dr. David Finkelman, M.D
Dr. David Finkelman, M.D is a Gastroenterology healthcare provider based in Hiram, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063485332.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Finkelman, M.D has received a total of $4,162 in payments from pharmaceutical and medical device companies, with $579.16 received in 2024. These payments were reported across 240 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($4,143).
As a Medicare-enrolled provider, Finkelman has provided services to 1,869 Medicare beneficiaries, totaling 2,499 services with total Medicare billing of $209,072. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Hiram, GA
- Active Since 02/08/2006
- Last Updated 09/05/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1063485332
Products in Payments
- XIFAXAN (Drug) $531.55
- DUPIXENT (Biological) $410.67
- LINZESS (Drug) $387.76
- HUMIRA (Biological) $212.18
- Humira (Biological) $208.71
- DIFICID (Drug) $179.96
- SKYRIZI (Biological) $152.77
- VIBERZI (Drug) $149.29
- ZEPOSIA (Drug) $140.22
- STELARA (Biological) $133.17
- RINVOQ (Biological) $127.32
- Sucraid (Drug) $124.84
- Linzess (Drug) $95.59
- RELISTOR ORAL (Drug) $90.78
- Creon (Drug) $88.64
- MAVYRET (Drug) $88.58
- OCALIVA (Drug) $84.65
- REMICADE (Biological) $69.44
- Cimzia (Drug) $69.41
- ZENPEP (Drug) $59.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Hiram
Florence Hosseini Aslinia, Md, MD
Gastroenterology — Payments: $22,823
Gastroenterology $22,823
Judy Oh, Md, MD
Gastroenterology — Payments: $1,928
Gastroenterology $1,928
Michael Grupka, Md, MD
Gastroenterology — Payments: $796.61
Gastroenterology $796.61
Philip Oppong-Twene, Md, MD
Gastroenterology — Payments: $109.09
Gastroenterology $109.09